- Home
- CRF vs PHAT Comparison
CRF vs PHAT Comparison
Compare CRF & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRF
- PHAT
- Stock Information
- Founded
- CRF 1973
- PHAT 2018
- Country
- CRF United States
- PHAT United States
- Employees
- CRF N/A
- PHAT N/A
- Industry
- CRF Finance/Investors Services
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- CRF Finance
- PHAT Health Care
- Exchange
- CRF Nasdaq
- PHAT Nasdaq
- Market Cap
- CRF 953.9M
- PHAT 835.7M
- IPO Year
- CRF N/A
- PHAT 2019
- Fundamental
- Price
- CRF $8.10
- PHAT $12.21
- Analyst Decision
- CRF
- PHAT Strong Buy
- Analyst Count
- CRF 0
- PHAT 5
- Target Price
- CRF N/A
- PHAT $16.40
- AVG Volume (30 Days)
- CRF 1.1M
- PHAT 1.2M
- Earning Date
- CRF 01-01-0001
- PHAT 11-06-2025
- Dividend Yield
- CRF 18.10%
- PHAT N/A
- EPS Growth
- CRF N/A
- PHAT N/A
- EPS
- CRF 1.40
- PHAT N/A
- Revenue
- CRF $11,461,786.00
- PHAT $114,039,000.00
- Revenue This Year
- CRF N/A
- PHAT $213.11
- Revenue Next Year
- CRF N/A
- PHAT $91.84
- P/E Ratio
- CRF $5.38
- PHAT N/A
- Revenue Growth
- CRF 6.53
- PHAT 1049.82
- 52 Week Low
- CRF $5.70
- PHAT $2.21
- 52 Week High
- CRF $9.56
- PHAT $19.50
- Technical
- Relative Strength Index (RSI)
- CRF 67.03
- PHAT 56.82
- Support Level
- CRF $7.87
- PHAT $11.74
- Resistance Level
- CRF $8.11
- PHAT $12.49
- Average True Range (ATR)
- CRF 0.06
- PHAT 0.70
- MACD
- CRF 0.01
- PHAT -0.02
- Stochastic Oscillator
- CRF 85.00
- PHAT 78.02
About CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.